Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances
Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needsTryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indicationsThe company expects to begin manufacturing its initial oral psilocybin formulation in September 2021Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and…